Numerous product recalls draw complaints from Johnson & Johnson shareholders

Posted
by Michael Heygood

During an annual meeting held this week, Johnson & Johnson shareholders criticized the company’s business practices. Shareholders raised concerns about excessive executive pay at the company as well as a number of high profile product recalls of Johnson & Johnson products in recent years.

One of the best known brands on the planet, Johnson & Johnson has come under fire in recent years as an alarming number of product recalls have raised concerns about the company. Some of the most widely publicized of these product recalls include:

  • August 2008: Johnson & Johnson secretly buys defective Motrin products back from stores. The Food and Drug Administration later states that it was not notified of this “phantom recall.”
  • December 2009: J&J recalls all batches of its Tylenol Arthritis Pain Caplets because of a “moldy odor” that was causing stomach symptoms in patients.
  • January 2010: Massive recall of Tylenol, Motrin, and St. Joseph’s aspirin products due to “moldy odor.” The FDA stated that J&J failed to correct the manufacturing issues that prompted the recall despite knowing of the problem since 2008.
  • May 2010: J&J recalls about 50 different versions of children’s Tylenol, Motrin, Benadryl and other over-the-counter drugs due to quality control problems. J&J was forced to close the plant where these drugs were made due to manufacturing problems identified by the FDA.
  • August 2010: J&J’s DePuy Orthopaedics unit recalls the metal-on-metal DePuy ASR XL Acetabular System and ASR Hip Resurfacing System hip replacements after researchers found the devices were more likely to fail prematurely than other hip replacements.
  • December 2010: Recall involving 12 million bottles of Mylanta and 85,000 bottles of Alternagel antacid products.
  • February 2011: J&J recalls 70,000 syringes preloaded with the antipsychotic drug Invega due to concerns that the vials could be cracked.
  • March 2011: 585,000 surgical sutures recalled by J&J due to concerns about their sterility.
  • February 2012: Recall of 574,000 bottles of grape-flavored Children’s Tylenol due to concerns about a risk of dosing errors.
  • June 2012: Fentanyl recall issued for 53,000 Duragesic brand patches manufactured by J&J after a manufacturing defect was uncovered that could pose a danger to patients.
  • July 2012: J&J’s Ethicon division recalls four Gynecare models of transvaginal surgical mesh products due to concerns about the side effects risk of these devices.
  • March 2013: OneTouch VerioIQ blood glucose meters recalled due to errors when reading high glucose levels.
  • April 2013: Recall of Animas 2020 Insulin Infusion Pump due to false alarms that could cause too much insulin to be delivered to a patient.

The numerous recall notices issued by Johnson & Johnson have already prompted lawsuits against the company. Thousands of patients who used one of the recalled DePuy hip replacements have filed lawsuits against Johnson & Johnson after they were forced to replace a failed hip replacement or experienced other problems with their device.

Patients who have experienced problems with DePuy hip replacement or other defective products manufactured by Johnson & Johnson may be eligible to file a lawsuit against the company. Although the FDA has ordered Johnson & Johnson to take preventative measures to address the manufacturing defects and other problems that have prompted this flood of recall notices by the company, Johnson & Johnson products are still being pulled from stores as recently as this month.

For more information about filing a lawsuit, contact the lawyers at Heygood, Orr & Pearson to learn more about whether you may be eligible to file a case. You can reach us by calling our toll-free hotline at 1-877-446-9001, or by filling out the free case evaluation form at the top of this page. After reviewing your information, one of our representatives will be in touch with you as soon as possible to find out more about your case.